SG11201704829QA - Methods and compositions for treating brain diseases - Google Patents

Methods and compositions for treating brain diseases

Info

Publication number
SG11201704829QA
SG11201704829QA SG11201704829QA SG11201704829QA SG11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
brain diseases
treating brain
treating
Prior art date
Application number
SG11201704829QA
Inventor
Beverly L Davidson
John H Lee
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of SG11201704829QA publication Critical patent/SG11201704829QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002Small monomeric GTPase (3.6.5.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201704829QA 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases SG11201704829QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098085P 2014-12-30 2014-12-30
PCT/US2015/068034 WO2016109649A1 (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Publications (1)

Publication Number Publication Date
SG11201704829QA true SG11201704829QA (en) 2017-07-28

Family

ID=56285031

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704829QA SG11201704829QA (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Country Status (12)

Country Link
US (1) US11612641B2 (en)
EP (1) EP3240577B1 (en)
JP (1) JP6782701B2 (en)
KR (1) KR102618947B1 (en)
CN (1) CN107405414A (en)
AU (1) AU2015374043B2 (en)
BR (1) BR112017013674A2 (en)
CA (1) CA2971687C (en)
ES (1) ES2962439T3 (en)
HK (1) HK1245127A1 (en)
SG (1) SG11201704829QA (en)
WO (1) WO2016109649A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114717264A (en) 2014-11-14 2022-07-08 沃雅戈治疗公司 Compositions and methods for treating Amyotrophic Lateral Sclerosis (ALS)
AU2015346164B2 (en) 2014-11-14 2020-01-30 Voyager Therapeutics, Inc. Modulatory polynucleotides
ES2962439T3 (en) 2014-12-30 2024-03-19 Univ Iowa Res Found Therapeutic agent that activates mTORC1 function for use in the treatment of Huntington's disease
KR20240056729A (en) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. Modulatory polynucleotides
KR102427379B1 (en) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. Compositions and methods for treating Huntington's disease
CL2016003282A1 (en) * 2016-12-21 2017-08-18 Univ Chile Aav / igf2 virus, method of genetic treatment and its use in diseases related to protein misfolding such as huntington's disease
WO2018132791A1 (en) 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050009112A1 (en) 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
KR20080018874A (en) 2005-04-27 2008-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. Materials and methods for enhanced degradation of mutant proteins associated with human disease
KR101286870B1 (en) * 2009-11-30 2013-07-16 (주)아모레퍼시픽 Composition for improving metabolism containing extraction of Astragali Radix
WO2013061305A1 (en) * 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013067125A1 (en) * 2011-11-01 2013-05-10 Children's Medical Center Corporation Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration
CN106994126A (en) 2011-11-08 2017-08-01 因特利凯有限责任公司 Use the therapeutic scheme of various medicaments
US9095521B2 (en) * 2012-02-02 2015-08-04 Washington University Methods for improving muscle strength
KR101626526B1 (en) 2014-10-30 2016-06-02 경북대학교 산학협력단 Composition comprising hRheb for preventing or treating Ischemic Brain disease
ES2962439T3 (en) 2014-12-30 2024-03-19 Univ Iowa Res Found Therapeutic agent that activates mTORC1 function for use in the treatment of Huntington's disease

Also Published As

Publication number Publication date
EP3240577B1 (en) 2023-07-05
WO2016109649A1 (en) 2016-07-07
HK1245127A1 (en) 2018-08-24
JP2018502112A (en) 2018-01-25
CA2971687C (en) 2024-05-28
CN107405414A (en) 2017-11-28
AU2015374043A1 (en) 2017-07-13
JP6782701B2 (en) 2020-11-11
BR112017013674A2 (en) 2018-02-06
AU2015374043B2 (en) 2021-05-13
US20180000907A1 (en) 2018-01-04
CA2971687A1 (en) 2016-07-07
EP3240577A1 (en) 2017-11-08
EP3240577A4 (en) 2018-07-25
ES2962439T3 (en) 2024-03-19
KR102618947B1 (en) 2023-12-27
KR20170098931A (en) 2017-08-30
US11612641B2 (en) 2023-03-28

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating ocular diseases
HK1232141A1 (en) Methods and compositions for treating huntingtons disease
ZA201705673B (en) Methods for treating skin
IL252159A0 (en) Methods and formulations for treating vascular eye diseases
HK1225305A1 (en) Methods and compositions for treating brain diseases
IL246791A0 (en) Compositions and methods for treating ocular diseases
HK1246179A1 (en) Methods of treating retinal diseases
HK1254432A1 (en) Methods and compositions for treating fibrotic diseases
HK1245127A1 (en) Methods and compositions for treating brain diseases
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
HK1258994A1 (en) Methods for treatment of diseases
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
HK1246206A1 (en) Compositions and methods for treating glaucoma
EP3262065C0 (en) Methods and compositions for treating dystroglycanopathy disorders
IL252904A0 (en) Methods and agents for treating disease
HK1244782A1 (en) Compositions and methods for treating diseases and conditions
HK1243937A1 (en) Methods of treating diseases
GB201521083D0 (en) Compositions for treatment and methods thereof
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes